Navamedic Completes Acquisition of dne pharma Business

Deal News | Jul 15, 2025 | PR Newswire Cision Navamedic ASA

Navamedic ASA, a Nordic pharmaceutical company, has successfully closed the acquisition of dne pharma AS's business for a total consideration of up to NOK 225 million. The deal includes an upfront payment of NOK 185 million, with an additional NOK 40 million contingent on sales milestones. The acquisition encompasses dne pharma's product portfolio, intellectual property, and essential contracts, and is expected to enhance Navamedic's presence in the addiction treatment market across the Nordics and select European territories. Financing for the acquisition is facilitated through a combination of new debt from Nordea Bank and a rights issue, with support from advisors DNB Carnegie and Thommessen. The acquisition aligns with Navamedic's strategic growth plans, aiming to expand in the addiction treatment sector.

Sectors

  • Pharmaceuticals
  • Healthcare
  • Finance

Geography

  • Norway – Both Navamedic ASA and dne pharma AS are based in Norway, and the acquisition takes place within the Norwegian legal and regulatory framework.
  • Europe – The acquisition facilitates market expansion for Navamedic into the Nordics and selected European markets.

Industry

  • Pharmaceuticals – The article involves the acquisition of dne pharma by Navamedic, both of which are companies in the pharmaceutical industry focusing on addiction and pain therapies.
  • Healthcare – The transaction emphasizes products related to addiction treatment, contributing to public health solutions, which are under the broader healthcare sector.
  • Finance – The acquisition involves financial arrangements such as a rights issue and bank loans, indicating a significant financial aspect in the structuring of the deal.

Financials

  • NOK 225 million – Total consideration for the acquisition of dne pharma by Navamedic.
  • NOK 185 million – Initial payment made at the closing of the acquisition.
  • NOK 40 million – Contingent payments subject to sales milestones.
  • NOK 110 million – Amount of new debt financing provided by Nordea Bank.

Participants

NameRoleTypeDescription
Navamedic ASAAcquirerCompanyA Nordic pharmaceutical company headquartered in Oslo, Norway, focusing on prescription, consumer health, and hospital products.
dne pharma ASTarget CompanyCompanyA Norwegian company specializing in addiction and pain therapies, including opioid substitution treatments.
Nordea Bank Abp, filial i NorgeFinancierCompanyA bank providing new debt financing for the acquisition.
DNB CarnegieFinancial AdvisorCompanyPart of DNB Bank ASA, involved in advising on the acquisition and the rights issue.
Advokatfirmaet ThommessenLegal AdvisorCompanyA law firm providing legal advisory services for the acquisition and rights issue.
Kathrine Gamborg AndreassenCEOPersonCEO of Navamedic ASA.
Geir Ove EngesetCEOPersonCEO of dne pharma AS.